Lidokain/Adrenalin Aguettant (Epinephrine, Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, which prevents the initiation and propagation of nerve impulses. By inhibiting these signals, it produces a reversible loss of sensation in the area where it is administered.

The specific dose of Lidokain/Adrenalin is determined by the prescribing clinician based on the type of procedure, patient weight, and clinical setting. Healthcare professionals calculate the appropriate volume and concentration to stay within recommended safety limits.

Safety data for Lidokain/Adrenalin during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Plain lidocaine provides rapid local anesthesia but has a shorter duration and may cause more bleeding at the injection site. Adding epinephrine, as in Lidokain/Adrenalin, causes vasoconstriction, which prolongs anesthesia, reduces systemic absorption, and minimizes intra‑procedural bleeding, making it preferable for many surgical applications.

Lidokain/Adrenalin should be stored at room temperature, below 25 °C, in its original sealed container. Protect the solution from direct light and moisture. Do not freeze. Inspect the vial for particulate matter before use and discard if the solution appears discolored or contaminated.

The product is administered by a qualified healthcare professional via injection. It can be given epidurally, infiltratively, or perineurally, depending on the intended procedure. Proper aseptic technique and dosage calculation are essential to ensure safety and effectiveness.

Serious risks include severe allergic reactions (anaphylaxis), cardiac arrhythmias, seizures, methemoglobinemia, and profound hypertension. Immediate medical attention is required if any of these events occur during or after administration.

Patients with known hypersensitivity to lidocaine, epinephrine, or any component of the formulation should avoid this product. It is also contraindicated in areas of infection, in patients with uncontrolled hyperthyroidism, or in those receiving non‑selective beta‑blockers where epinephrine effects may be unpredictable.